Accuray (ARAY) Competitors $1.82 +0.01 (+0.28%) (As of 11:30 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARAY vs. UTMD, ANIK, CTSO, SPNE, OFIX, SRDX, ANGO, RMTI, RSLS, and ABTShould you be buying Accuray stock or one of its competitors? The main competitors of Accuray include Utah Medical Products (UTMD), Anika Therapeutics (ANIK), Cytosorbents (CTSO), SeaSpine (SPNE), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "medical" sector. Accuray vs. Utah Medical Products Anika Therapeutics Cytosorbents SeaSpine Orthofix Medical Surmodics AngioDynamics Rockwell Medical ReShape Lifesciences Abbott Laboratories Utah Medical Products (NASDAQ:UTMD) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking. Do institutionals and insiders believe in UTMD or ARAY? 69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 6.6% of Utah Medical Products shares are owned by insiders. Comparatively, 4.2% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, UTMD or ARAY? Utah Medical Products has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUtah Medical Products$44.08M5.25$16.64M$4.2715.57Accuray$446.55M0.41-$15.55M-$0.17-10.68 Do analysts rate UTMD or ARAY? Accuray has a consensus price target of $9.00, indicating a potential upside of 395.87%. Given Accuray's stronger consensus rating and higher probable upside, analysts plainly believe Accuray is more favorable than Utah Medical Products.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Accuray 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, UTMD or ARAY? Utah Medical Products has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Does the media favor UTMD or ARAY? In the previous week, Utah Medical Products and Utah Medical Products both had 2 articles in the media. Utah Medical Products' average media sentiment score of 1.18 beat Accuray's score of 0.81 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Accuray 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor UTMD or ARAY? Accuray received 178 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 65.74% of users gave Accuray an outperform vote while only 61.60% of users gave Utah Medical Products an outperform vote. CompanyUnderperformOutperformUtah Medical ProductsOutperform Votes15461.60% Underperform Votes9638.40% AccurayOutperform Votes33265.74% Underperform Votes17334.26% Is UTMD or ARAY more profitable? Utah Medical Products has a net margin of 34.62% compared to Accuray's net margin of -3.72%. Utah Medical Products' return on equity of 12.04% beat Accuray's return on equity.Company Net Margins Return on Equity Return on Assets Utah Medical Products34.62% 12.04% 11.42% Accuray -3.72%-36.93%-3.52% SummaryUtah Medical Products beats Accuray on 10 of the 17 factors compared between the two stocks. Ad Golden CrestIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Get Accuray News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAY vs. The Competition Export to ExcelMetricAccuraySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$182.54M$4.61B$5.18B$8.91BDividend YieldN/A39.52%4.98%4.03%P/E Ratio-10.6825.03135.1217.44Price / Sales0.4160.921,248.6491.11Price / CashN/A52.4438.8936.42Price / Book4.035.576.305.92Net Income-$15.55M$13.58M$118.33M$224.86M7 Day Performance-13.16%-1.20%-1.54%-0.45%1 Month Performance0.83%6.17%2.98%4.16%1 Year Performance-32.28%54.99%36.39%27.33% Accuray Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAYAccuray4.7941 of 5 stars$1.82+0.3%$9.00+395.9%-29.0%$182.54M$446.55M-10.68987UTMDUtah Medical Products3.6259 of 5 stars$67.23+0.1%N/A-17.8%$233.96M$50.22M15.74180Positive NewsANIKAnika Therapeutics3.8802 of 5 stars$17.23-0.2%N/A-16.1%$252.58M$166.66M-2.59357CTSOCytosorbents1.6698 of 5 stars$0.90-2.2%N/A-28.2%$49.15M$36.35M-1.70186Analyst ForecastAnalyst RevisionSPNESeaSpine0.5498 of 5 stars$9.54flatN/A+0.0%$354.92M$191.45M-5.39523Gap DownOFIXOrthofix Medical1.2784 of 5 stars$18.22-1.0%N/A+92.4%$695.55M$771.65M-5.711,634Gap UpSRDXSurmodics4.3582 of 5 stars$38.40-0.2%N/A+18.0%$547.85M$120.82M-384.00376Analyst RevisionPositive NewsANGOAngioDynamics4.7622 of 5 stars$7.15-3.5%N/A+9.2%$273.88M$303.91M-1.17748Short Interest ↓Positive NewsRMTIRockwell Medical4.1969 of 5 stars$4.19+1.7%N/A+33.5%$130.02M$83.61M-24.65300Earnings ReportAnalyst UpgradeNews CoverageGap UpRSLSReShape Lifesciences0.3305 of 5 stars$5.38-8.7%N/A-61.2%$2.74M$8.68M0.0050Short Interest ↑ABTAbbott Laboratories4.9885 of 5 stars$115.31-1.3%N/A+20.8%$204.06B$40.11B35.05114,000Positive News Related Companies and Tools Related Companies UTMD Alternatives ANIK Alternatives CTSO Alternatives SPNE Alternatives OFIX Alternatives SRDX Alternatives ANGO Alternatives RMTI Alternatives RSLS Alternatives ABT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARAY) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accuray Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Accuray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
